Le Lézard

Sucheta Kamath, CEO & Founder, ExQ, launches the Executive Function Advocacy Toolkit to raise awareness of the value and impact of teaching Executive Function skills

Sucheta Kamath, CEO & Founder, ExQ,  launches the Executive Function Advocacy Toolkit to raise awareness for the value and impact of teaching Executive Function skills, the cognitive and affective ...
PharmiWeb

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
MedPage Today

New Drug for Rare Neuroendocrine Tumors Shows Durable Activity

BERLIN -- Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...